Alterity Therapeutics Ltd

ATH

Company Profile

  • Business description

    Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson’s disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

  • Contact

    350 Collins Street
    Suite 4, Level 14
    MelbourneVIC3000
    AUS

    T: +61 393494906

    E: [email protected]

    https://www.alteritytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    9

Stocks News & Analysis

stocks

Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%

We see faster cloud growth and improved longer-term profitability for Alphabet.
stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,317.2026.50-0.28%
CAC 408,225.630.15-0.00%
DAX 4024,239.8932.100.13%
Dow JONES (US)47,207.12472.511.01%
FTSE 1009,645.6267.050.70%
HKSE26,160.15192.170.74%
NASDAQ23,204.87263.071.15%
Nikkei 22549,299.65658.041.35%
NZX 50 Index13,391.5914.490.11%
S&P 5006,791.6953.250.79%
S&P/ASX 2009,019.0025.20-0.28%
SSE Composite Index3,950.3127.900.71%

Market Movers